25 February 2019 – The Board of leading medicinal cannabis company AusCann Group Holdings Limited (ASX:AC8) (‘AusCann’ or ‘the Company’) is pleased to announce the appointment of global pharmaceutical business executive, Mr. Ido Kanyon, as Chief Executive Officer (CEO), commencing 22nd May 2019.
Mr. Kanyon brings more than 15 years’ senior executive experience in the pharmaceutical industry most recently at Teva Pharmaceutical Industries (‘Teva’), the world's largest generic pharmaceutical company which also specialized in the development and commercialization of active pharmaceutical ingredients and specialty proprietary medicines. Teva is listed on the NYSE with FY17 revenues of over US$22 billion.
For further information please download PDF attached:
Download this document